There are still no clinical trials in humans, but the results are hard to ignore
Clinical trials show that patients on semaglutide lose an average of 510% of their starting body weight within the first 12 weeks
A recurrence rate of 32% and a metastates rate ranging from 13% to 44% has been reported, therefore all cases should be considered potentially malignant
Symptoms, Causes, Diagnosis, Treatment, and Prevention What Are Allergies
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial
This test specifically identifies whether you'll respond best to semaglutide, tirzepatide, or a dual-compound approach like GLP-Squaredeliminating months of trial-and-error with medications that don't match your biology